AstraZeneca CEO Soriot plays up to $ 7B on a major league partnership for a game exchange HER2 cancer use – Endpoints News
After years of outlicensing, product sales and everything else it took to float the descending AstraZeneca ship, CEO Pascal Soriot is now a buyer. And he goes great.
Thursday night, Soriot announced that AstraZeneca pays Daiichi Sankyo $ 1.35 billion in advance to the trastuzumab deruxtecan partner, an antibody-conjugate for HER2-expressing cancers. Half comes with the signing, the other half in a year. And Soriot adds up to $ 5.55 billion more in development and commercial milestones, totaling $ 6.9 billion, one of the biggest covenants the company has ever made.
In contrast to sharing development and commercialization costs, AstraZeneca will also share the profits ̵[ads1]1; which Soriot clearly believes have mega-blockbuster potential in oncology – a field that AstraZeneca has invested heavily in.
The Pharma giant finances the deal with a $ 3.5 billion sale in shares and expects a quick repayment, with H2 first-time registration.
"We believe that trastuzumab deruxtecan could become a transformative new medicine for the treatment of HER2-positive breast and stomach ulcers," said Soriot. "In addition, the trastuzumab deruxtecan [fam-] has the potential to redefine breast cancer treatment as the first therapy for HER2 low-expressing tumors, and also has the potential to treat other HER2 mutated or HER2 over-expressing tumors, including lung and colorectal cancers. proud to work with Daiichi Sankyo, a long-term partner in AstraZeneca in other disease areas. "
The agreement is possible because after 6 years Soriot has finally gained credibility in claiming cover after a long period of falling numbers. And he owes it to the success of Lynparza and Tagrisso and to some extent the PD-L1 control point Imfinzi.
If they succeed, the two parties share this way: Daiichi Sankyo will order sales in the US and some countries in Europe, as well as other markets where Daiichi Sankyo has affiliates. AstraZeneca is expected to order sales in all other markets worldwide, including China, Australia, Canada and Russia.
Daiichi Sankyo, CEO George Nakayama, called this drug "the flagship" in its oncological pipeline.
Here is ADC: 19659002] The drug is a "humanized HER2 antibody attached to a new topoisomerase I inhibitor payload of a tetrapeptide-based linker. It is designed to target and deliver chemotherapy within cancer cells and reduce systemic exposure to the cytotoxic The payload relative to the way chemotherapy is usually delivered. "
The drug (DS-8201) is in development for several HER2-expressing cancers, including breast and stomach cancer, with an increased focus on non-small cell lung and colorectal. cancer.
This covenant comes just a few months after Soriot has completed a top-to-bottom R&D revolution, eliminating his old MedImmune operation and splitting the developmental operation between cancer – new arrival Jose Baselga – and everything else under Mene Pangalos.
Pascal Soriot in Washington, DC, February 2019 Getty
